The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera

a randomized, double-blind, double-dummy, symptom study (RELIEF)

Ruben Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg, Roger Lyons, Steffen Koschmieder, Ciro Rinaldi, Jennifer Byrne, Yasmin Hasan, Francesco Passamonti, Srdan Verstovsek, Deborah Hunter, Mark M. Jones, Huiling Zhen, Dany Habr, Bruno Martino

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The randomized, double-blind, double-dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)-related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV-related symptoms. Patients were randomized 1:1 to ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, ≥50% improvement from baseline in myeloproliferative neoplasm -symptom assessment form total symptom score cytokine symptom cluster (TSS-C; sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at Week 16, was achieved by 43·4% vs. 29·6% of ruxolitinib- and hydroxycarbamide-treated patients, respectively (odds ratio, 1·82; 95% confidence interval, 0·82–4·04; P = 0·139). The primary endpoint was achieved by 34% of a subgroup who maintained their hydroxycarbamide dose from baseline to Weeks 13–16. In a post hoc analysis, the primary endpoint was achieved by more patients with stable screening-to-baseline TSS-C scores (ratio ≤ 2) receiving ruxolitinib than hydroxycarbamide (47·4% vs. 25·0%; P = 0·0346). Ruxolitinib treatment after unblinding was associated with continued symptom score improvements. Adverse events were primarily grades 1/2 with no unexpected safety signals. Ruxolitinib was associated with a nonsignificant trend towards improved PV-related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement.

Original languageEnglish (US)
Pages (from-to)76-85
Number of pages10
JournalBritish Journal of Haematology
Volume176
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Polycythemia Vera
Safety
Sweat
Therapeutics
Symptom Assessment
Hydroxyurea
Pruritus
INCB018424
Appointments and Schedules
Odds Ratio
Confidence Intervals
Cytokines
Pain
Muscles
Neoplasms

Keywords

  • hydroxycarbamide
  • Janus kinase
  • polycythaemia vera
  • quality of life
  • signs and symptoms

ASJC Scopus subject areas

  • Hematology

Cite this

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera : a randomized, double-blind, double-dummy, symptom study (RELIEF). / Mesa, Ruben; Vannucchi, Alessandro M.; Yacoub, Abdulraheem; Zachee, Pierre; Garg, Mamta; Lyons, Roger; Koschmieder, Steffen; Rinaldi, Ciro; Byrne, Jennifer; Hasan, Yasmin; Passamonti, Francesco; Verstovsek, Srdan; Hunter, Deborah; Jones, Mark M.; Zhen, Huiling; Habr, Dany; Martino, Bruno.

In: British Journal of Haematology, Vol. 176, No. 1, 01.01.2017, p. 76-85.

Research output: Contribution to journalArticle

Mesa, R, Vannucchi, AM, Yacoub, A, Zachee, P, Garg, M, Lyons, R, Koschmieder, S, Rinaldi, C, Byrne, J, Hasan, Y, Passamonti, F, Verstovsek, S, Hunter, D, Jones, MM, Zhen, H, Habr, D & Martino, B 2017, 'The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)', British Journal of Haematology, vol. 176, no. 1, pp. 76-85. https://doi.org/10.1111/bjh.14382
Mesa, Ruben ; Vannucchi, Alessandro M. ; Yacoub, Abdulraheem ; Zachee, Pierre ; Garg, Mamta ; Lyons, Roger ; Koschmieder, Steffen ; Rinaldi, Ciro ; Byrne, Jennifer ; Hasan, Yasmin ; Passamonti, Francesco ; Verstovsek, Srdan ; Hunter, Deborah ; Jones, Mark M. ; Zhen, Huiling ; Habr, Dany ; Martino, Bruno. / The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera : a randomized, double-blind, double-dummy, symptom study (RELIEF). In: British Journal of Haematology. 2017 ; Vol. 176, No. 1. pp. 76-85.
@article{ea8966cd11ba4b62ac1abd027f1ad495,
title = "The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)",
abstract = "The randomized, double-blind, double-dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)-related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV-related symptoms. Patients were randomized 1:1 to ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, ≥50{\%} improvement from baseline in myeloproliferative neoplasm -symptom assessment form total symptom score cytokine symptom cluster (TSS-C; sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at Week 16, was achieved by 43·4{\%} vs. 29·6{\%} of ruxolitinib- and hydroxycarbamide-treated patients, respectively (odds ratio, 1·82; 95{\%} confidence interval, 0·82–4·04; P = 0·139). The primary endpoint was achieved by 34{\%} of a subgroup who maintained their hydroxycarbamide dose from baseline to Weeks 13–16. In a post hoc analysis, the primary endpoint was achieved by more patients with stable screening-to-baseline TSS-C scores (ratio ≤ 2) receiving ruxolitinib than hydroxycarbamide (47·4{\%} vs. 25·0{\%}; P = 0·0346). Ruxolitinib treatment after unblinding was associated with continued symptom score improvements. Adverse events were primarily grades 1/2 with no unexpected safety signals. Ruxolitinib was associated with a nonsignificant trend towards improved PV-related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement.",
keywords = "hydroxycarbamide, Janus kinase, polycythaemia vera, quality of life, signs and symptoms",
author = "Ruben Mesa and Vannucchi, {Alessandro M.} and Abdulraheem Yacoub and Pierre Zachee and Mamta Garg and Roger Lyons and Steffen Koschmieder and Ciro Rinaldi and Jennifer Byrne and Yasmin Hasan and Francesco Passamonti and Srdan Verstovsek and Deborah Hunter and Jones, {Mark M.} and Huiling Zhen and Dany Habr and Bruno Martino",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/bjh.14382",
language = "English (US)",
volume = "176",
pages = "76--85",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera

T2 - a randomized, double-blind, double-dummy, symptom study (RELIEF)

AU - Mesa, Ruben

AU - Vannucchi, Alessandro M.

AU - Yacoub, Abdulraheem

AU - Zachee, Pierre

AU - Garg, Mamta

AU - Lyons, Roger

AU - Koschmieder, Steffen

AU - Rinaldi, Ciro

AU - Byrne, Jennifer

AU - Hasan, Yasmin

AU - Passamonti, Francesco

AU - Verstovsek, Srdan

AU - Hunter, Deborah

AU - Jones, Mark M.

AU - Zhen, Huiling

AU - Habr, Dany

AU - Martino, Bruno

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The randomized, double-blind, double-dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)-related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV-related symptoms. Patients were randomized 1:1 to ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, ≥50% improvement from baseline in myeloproliferative neoplasm -symptom assessment form total symptom score cytokine symptom cluster (TSS-C; sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at Week 16, was achieved by 43·4% vs. 29·6% of ruxolitinib- and hydroxycarbamide-treated patients, respectively (odds ratio, 1·82; 95% confidence interval, 0·82–4·04; P = 0·139). The primary endpoint was achieved by 34% of a subgroup who maintained their hydroxycarbamide dose from baseline to Weeks 13–16. In a post hoc analysis, the primary endpoint was achieved by more patients with stable screening-to-baseline TSS-C scores (ratio ≤ 2) receiving ruxolitinib than hydroxycarbamide (47·4% vs. 25·0%; P = 0·0346). Ruxolitinib treatment after unblinding was associated with continued symptom score improvements. Adverse events were primarily grades 1/2 with no unexpected safety signals. Ruxolitinib was associated with a nonsignificant trend towards improved PV-related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement.

AB - The randomized, double-blind, double-dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)-related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV-related symptoms. Patients were randomized 1:1 to ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, ≥50% improvement from baseline in myeloproliferative neoplasm -symptom assessment form total symptom score cytokine symptom cluster (TSS-C; sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at Week 16, was achieved by 43·4% vs. 29·6% of ruxolitinib- and hydroxycarbamide-treated patients, respectively (odds ratio, 1·82; 95% confidence interval, 0·82–4·04; P = 0·139). The primary endpoint was achieved by 34% of a subgroup who maintained their hydroxycarbamide dose from baseline to Weeks 13–16. In a post hoc analysis, the primary endpoint was achieved by more patients with stable screening-to-baseline TSS-C scores (ratio ≤ 2) receiving ruxolitinib than hydroxycarbamide (47·4% vs. 25·0%; P = 0·0346). Ruxolitinib treatment after unblinding was associated with continued symptom score improvements. Adverse events were primarily grades 1/2 with no unexpected safety signals. Ruxolitinib was associated with a nonsignificant trend towards improved PV-related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement.

KW - hydroxycarbamide

KW - Janus kinase

KW - polycythaemia vera

KW - quality of life

KW - signs and symptoms

UR - http://www.scopus.com/inward/record.url?scp=84998579409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998579409&partnerID=8YFLogxK

U2 - 10.1111/bjh.14382

DO - 10.1111/bjh.14382

M3 - Article

VL - 176

SP - 76

EP - 85

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -